A2AR Expression and Immunosuppressive Environment Independent of KRAS and GNAS Mutations in Pseudomyxoma Peritonei
Authors:
- Shigeki KusamuraSKShigeki Kusamura
- Adele BusicoABAdele Busico
- Elena ConcaECElena Conca
- Iolanda CaponeICIolanda Capone
- Luca AgnelliLuca Agnelli
- Daniele LorenziniDLDaniele Lorenzini
- Silvia BrichSBSilvia Brich
- Marta AngeliniMAMarta Angelini
- Chiara Costanza VolpiCVChiara Costanza Volpi
- Desirè Viola TrupiaDTDesirè Viola Trupia
- Vincenzo LaganoVLVincenzo Lagano
- Tommaso TorelliTTTommaso Torelli
Open Access
- 20 July 2023
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 11 (7) , 2049
Abstract
In pseudomyxoma peritonei (PMP), KRAS and GNAS mutations are frequent. We hypothesized that these mutations may contribute to the suppression of antitumor immunity: KRAS may induce GMCSF expression, while GNAS may enhance the expression of cyclic adenosine monophosphate and A2AR signaling. This study aimed to explore possible mechanisms facilitated by KRAS and GNAS mutations for escaping immune surveillance. Additionally, we looked for new potential therapeutic and prognostic targets in this rare disease which is poorly characterized at the molecular level. GM-CSF, A2AR, CD73, CD39, and PD-L1 expression was investigated by immunohistochemistry in 40 PMPs characterized for GNAS and KRAS mutational status. Immune cell populations were studied by immunohistochemistry and nanostring nCounter®. Following the criteria of a prognostic nomogram reported for PMP, we stratified the patients into two different risk groups, with 28 “low-risk” and 12 “high-risk” patients. We observed the expression of GM-CSF (74%); CD39 (37%); CD73 (53%); A2AR (74%); and PD-L1 (16%) which was unrelated to GNAS or KRAS status. The tumor microenvironment showed the presence of CD4+ T cells (86%); CD8+ T cells (27%); CD20+ B (67%); CD15+ cells (86%); and CD163+ M2 macrophages (67%), while CD56+ NK cells were absent. CD163 expression (27%) in PMP tumor cells was associated with poor prognosis. GNAS mutation and A2AR expression were not associated with a specific immune transcriptional signature. However, the expression assay revealed 21 genes associated with prognosis. The “high-risk” patients exhibited worse progression-free survival (HR = 2.3, CI 95%: 1.1–5.1, p = 0.034) and significant downregulation of MET, IL8, PPARG, DTX4, HMGA1, ZIC2, WNT5B, and CCRL2. In conclusion, we documented the presence of immunosuppressive factors such as GM-CSF, A2AR, and PD-L1 in PMP. These factors were not associated with GNAS and KRAS status and could be explored as therapeutic molecular targets. Additionally, a set of potential prognostic biomarkers, including CD163 expression in tumor cells, deserve further investigation.Keywords
Funding Information
- AIRC IG 2016 (Id.19206PI MD)
This publication has 35 references indexed in Scilit:
- Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic NeoplasiaCancer Discovery, 2016
- Purinergic regulation of the immune systemNature Reviews Immunology, 2016
- NF-κB enhances hypoxia-driven T-cell immunosuppression via upregulation of adenosine A2A receptorsCellular Signalling, 2014
- Immunity, inflammation and cancer: a leading role for adenosineNature Reviews Cancer, 2013
- Differential Expression of IL-17, 22 and 23 in the Progression of Colorectal Cancer in Patients with K-ras Mutation: Ras Signal Inhibition and Crosstalk with GM-CSF and IFN-γPLOS ONE, 2013
- Oncogenic Kras-Induced GM-CSF Production Promotes the Development of Pancreatic NeoplasiaCancer Cell, 2012
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences, 2006
- New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?The Lancet Oncology, 2006
- De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependentCancer Cell, 2005